menu
    • menu
    [{"orgOrder":0,"company":"Asimov","sponsor":"Ottimo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Partnership","leadProduct":"OTP-01","moa":"PD1\/VEGFR2","graph1":"Oncology","graph2":"Preclinical","graph3":"Asimov","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asimov \/ Ottimo Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Asimov \/ Ottimo Pharma"},{"orgOrder":0,"company":"Asimov","sponsor":"RevOpsis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"RO-104","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Asimov","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asimov \/ RevOpsis Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Asimov \/ RevOpsis Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Asimov

    Menu

    Asimov

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Asimov

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Asimov

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OTP-01

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Ottimo Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Asimov, Ottimo Pharma Enter Cell Line Development Partnership

                            Details : The collaboration centered on cell line development for Ottimo’s lead program, OTP-01, a PD1/VEGFR2 dual pathway antibody.

                            Product Name : OTP-01

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            August 27, 2025

                            Lead Product(s) : OTP-01

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Ottimo Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Asimov

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Asimov

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RO-104

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : RevOpsis Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Asimov Signs Agreement for High Titer Multispecific Cell Line Licensing with RevOpsis

                            Details : RevOpsis will integrate the CHO Edge System in the development and commercialization of its first-in-class fully modular tri-specific biologic, RO-104, for the treatment of retinal vascular diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 19, 2024

                            Lead Product(s) : RO-104

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : RevOpsis Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth